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Cope’s gray treefrog, Hyla chrysoscelis, is a 
freeze-tolerant amphibian that accumulates 
cryoprotective glycerol during cold accli-
mation (1,2). Control of intracellular and 
extracellular water content, and glycerol distri-
bution, promotes extracellular freezing while 
protecting intracellular structures from ice 
damage. Regulation of those water and glycerol 
fluxes is enhanced by aquaporins (AQPs) and 
aquaglyceroporins (GLPs), integral membrane 
proteins that facilitate water and, in some 
cases, glycerol flux across cell membranes 
(3). Of special interest to the physiology of 
freeze tolerance is the GLP HC-3, cloned and 
functionally characterized from H. chrysos-
celis (2). HC-3 is expressed in erythrocytes 
and other tissues (2,4,5), and HC-3 protein 
abundance in erythrocytes increases during 
cold acclimation (5). Although previous 
studies have shown a correlation between 
enhanced GLP expression, cryoprotection, 
and freeze tolerance (2,5–8), the functional 
role of these proteins in conferring freeze 
tolerance remains poorly understood. To 
address this question, an in vitro cell culture 
model system of HC-3–expressing cells was 
developed. Suspension cultures of eryth-
rocytes from H. chrysoscelis were chosen 
because they are nucleated, metabolically 
active, and therefore capable of regulating 
gene expression as well as peptide-mediated 
endocytosis, and can be repetitively harvested 
as a highly homogenous cell population. 
Since there are no specific inhibitors for 
AQPs/GLPs, and tools for gene knockout 
technology do not exist for H. chrysoscelis, an 
antisense phosphorodiamidate morpholino 
(PMO) knockdown approach was pursued. 
Antisense PMOs act on RNA targets by 
sterically blocking the translation initi-
ation complex (9). Techniques available for 
delivery of PMOs to cells in culture include 
syringe or scrape loading, lipsomes, cationic 
polymers, free uptake from the media, and 
electroporation (9). Electroporation has 
also been used in adult axolotl for studying 
tissue regeneration (10), whereas microin-
jection and electroporation are widely used 
for delivery of PMOs into nonmammalian 
developmental models including sea urchin, 
Xenopus, zebrafish, and Drosophila embryos 
(11). Endo-Porter (GeneTools, Philmoth, OR, 
USA) is a novel peptide that mediates PMO 
delivery through nonspecific endocytosis, 
is effective in a wide variety of cell types, is 
easy to use, and is nontoxic to cells (12). Endo-
Porter has been used in vitro to deliver PMOs 
to mammalian adherent and nonadherent 
cells cultured at 37°C (12,13) and ex vivo in 
tissue explants (14), resulting in a range of 
50–80% targeted expression knockdown. 
One recent study used Endo-Porter–mediated 
PMO delivery to target endogenous gene 
knockdown in cultured carp macrophages 
(15). Endo-Porter has also been used success-
fully to deliver PMOs in vivo in newts (16). 
To date, however, Endo-Porter has not been 
widely used in nonmammalian cell culture 
systems. The objective of this study was to 
determine under what conditions and with 
what efficiency Endo-Porter–mediated 
PMO delivery could be used to knock down 
targeted gene expression in nonmammalian 
cell suspension cultures, specifically in 
amphibian erythrocytes.
The HC-3 PMO was selected using the 
criteria defined for custom PMO design 
available through GeneTools. The HC-3 
antisense PMO sequence (5′-CCCATGT-
TGCTGAGCCTCTAGGTC-3′) was 
designed based on complementarity to the 
following region in HC-3 (indicated in 
brackets on the sense strand, with the start 
codon in parentheses): ACTACTCAGC-
CGGCAGCATCACAGCTCTCCCC 
[GACCTAGAGGCTCAGCAAC(ATG)
GG]GCGCCAGAAGGAGGTTCTCA. 
The commercially available standard control 
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Cope’s gray treefrog, Hyla chrysoscelis, is a freeze-tolerant anuran that accu-
mulates cryoprotective glycerol during cold acclimation. H. chrysoscelis eryth-
rocytes express the aquaglyceroporin HC-3, which facilitates transmembrane 
glycerol and water movement. Aquaglyceroporins have no pharmacological 
inhibitors, and no genetic knockout tools currently exist for H. chrysoscelis. 
A phosphorodiamidate morpholino oligo (PMO)–mediated expression 
knockdown approach was therefore pursued to provide a model for testing 
the role of HC-3. We describe a novel procedure optimized for specific, effi-
cient knockdown of HC-3 expression in amphibian erythrocyte suspensions 
cultured at nonmammalian physiological temperatures using Endo-Porter. 
Our protocol includes three critical components: pre-incubation at 37°C, 
two rounds of Endo-Porter and HC-3 PMO administration at ~23°C, and 
continuous shaking at 190 rpm. This combination of steps resulted in 94% 
reduction in HC-3 protein expression (Western blot), substantial decrease 
in HC-3 expression in >65% of erythrocytes, and no detectable expression 
in an additional 30% of cells (immunocytochemistry).
Benchmarks
Benchmarks
www.BioTechniques.com330Vol. 50 | No. 5 | 2011
oligo (5′-CCTCTTACCTCAGTTA-
CAATTTATA-3′; Gene Tools) with no 
known target in H. chrysoscelis was used as 
a PMO control.
The optimized procedure is as follows: 
Whole blood from H. chrysoscelis was 
collected in heparinized capillary tubes, 
transferred to 15-mL conical tubes containing 
5 mL complete cell culture media [CCCM; 
250 mOsM, RPMI 1640  medium supple-
mented with L-glutamine, 100 units/mL 
penicillin and streptomycin, 0.25 µg/mL 
amphotericin B (Invitrogen, Carlsbad, 
CA, USA), and 5% FBS (Fisher Scientific, 
Hanover Park, IL, USA)], centrifuged at 
1000× g for 10 min, and resuspended in 
CCCM. Approximately 2 × 106 cells were 
incubated in 200 µL media in round-bottom 
polypropylene tubes (Fisher Scientific) at 
37°C for 2 h while shaking at 190 rpm on 
a titer plate shaker (Lab-Line Instruments 
Inc., Melrose Park, IL, USA). The suspension 
volume was increased to 1 mL followed by 
addition of one of the following treatments: 
A, no treatment (control); B, 10 µM Endo-
Porter alone (EP); C, 3 µM HC-3 PMO alone 
(HC-3 M); D, 10 µM Endo-Porter and 3 µM 
HC-3 PMO (EP + HC-3 M); and E, 10 µM 
Endo-Porter and 3 µM standard control 
PMO (EP + control M). Endo-Porter and 
standard or HC-3 PMO were sequentially 
added to the erythrocyte cultures. Cultures 
were maintained at 22–25°C within the range 
of basal body temperature of live treefrogs for 
24 h while shaking. After 24 h, media was 
replaced with 200 µL fresh CCCM and 
erythrocytes were again incubated at 37°C 
for 2 h while shaking. At the end of 2 h, 
800 µL CCCM was added to each culture. 
The relevant cultures were spiked with an 
additional 3 µM control or HC-3 PMO 
and/or 10 µM Endo-Porter, and maintained 
for an additional 24 h at room temper-
ature after which the media was replaced; 
cells were cultured for a total of 76 h. Initial 
optimization experiments showed that cell 
viability at 76 h (~98%) remained unchanged 
between untreated erythrocytes and erythro-
cytes cultured in Endo-Porter alone (6–10 
µM), HC-3 PMO alone (3–10 µM), or 
Endo-Porter and HC-3 PMO (each at 10 
µM) (data not shown). At 76 h, total cellular 
proteins were isolated, size-fractionated 
by SDS-PAGE, and subjected to Western 
hybridization using a peptide-derived, 
monospecific rabbit polyclonal antibody 
raised against 16 C-terminal amino acids of 
HC-3 (0.44 µg/mL), or mouse anti–β-actin 
antibody, (diluted 1:5000; Sigma-Aldrich, 
St. Louis, MO, USA) followed by incubation 
with HRP-conjugated goat anti-rabbit 
secondary antibody (1:1000; Santa Cruz 
Biotech, Santa Cruz, CA, USA) or goat 
anti-mouse secondary antibody (1:1000; 
Santa Cruz Biotech) as previously described 
(5). Relative band intensities were determined 
by densitometry using Vision Works software 
on a BioSpectrum Imaging System (UVP, 
Upland, CA, USA). Averaged HC-3 protein 
abundance (normalized to β-actin) was 
expressed as a percentage of the no-treatment 
control group (A).
HC-3 protein abundance was reduced by 
94% in treated cultures (treatment D) and 
showed no change in control cultures (treat-
ments A–C and E) after 76 h, compared 
with no-treatment controls (Figure 1, 
A and B), indicating that HC-3 knockdown 
was specific to the Endo-Porter plus HC-3 
PMO treatment. Immunocytochemistry 
was performed (as previously described in 
Reference 5) on erythrocytes harvested at 76 h 
to examine the efficiency and degree of HC-3 
knockdown at the cellular level (Figure 2). 
Treatment D (Figure 2D) showed an overall 
75% reduction in HC-3 expression, assessed 
semiquantitatively from combined cellular 
fluorescence (corrected for cell number) of 
experimental relative to control groups (Figure 
2, A–C and E). Moreover, ~30% of erythro-
Figure 1. Western blot analysis of HC-3 protein expression in cultured erythrocytes. (A) Western blot-
ting was performed as previously described (5), on total cellular proteins isolated after 76 h from erythro-
cytes subjected to the following culture treatment combinations: Lane 1, no treatment (control); Lane 2, 
10 µM Endo-Porter alone (EP); Lane 3, 3 µM HC-3 PMO alone (HC-3 M); Lane 4, 10 µM Endo-Porter 
and 3 µM HC-3 PMO (EP + HC-3 M); Lane 5, 10 µM Endo-Porter and 3 µM standard control PMO 
(EP + control M). An affinity-purified peptide-derived anti-rabbit polyclonal antibody directed against 
the final 16 amino acids of the C terminus of the predicted H. chrysoscelis HC-3 protein (previously 
described in Reference 5) was used to detect native and glycosylated HC-3 protein at 33 kDa (arrow) 
and >65 kDa, respectively. Lane 6, pre-absorption control. Pre-incubation of the HC-3 polyclonal 
antibody with 200-fold excess of the immunizing peptide blocked HC-3–immunospecific reactivity at 
33 kDa and >65 kDa. A nonspecific band at 65 kDa not blocked by antibody pre-absorption with the 
immunizing peptide appears in all lanes. Expression of the housekeeping gene β-actin (42 kDa) as de-
termined by Western blotting with a mouse anti–β-actin antibody is shown as a gel loading control. (B) 
HC-3 and β-actin expression was quantified by densitometry. For each treatment combination, HC-3 
protein expression (normalized to β-actin) is expressed as a relative percentage versus normalized HC-3 
expression in erythrocytes with no treatment. HC-3 protein expression in treated cultures (EP+HC-3 M) 
is reduced by an average of 94% with a range of 92–96% (n = 4).
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cytes showed complete HC-3 knockdown 
as assessed by the absence of fluorescence 
(Figure 2D), while >65% of erythrocytes 
had substantial reduction in HC-3 expression 
compared with treatment controls (Figure 2, 
A–C and E). Pre-incubation of the primary 
antibody with the immunizing peptide 
resulted in no immunoreactive signal 
(Figure 1A and Figure 2F), indicating that 
the signal observed in panels A–E is immuno-
specific for the HC-3 antibody. Thus, a high 
efficiency (>95%) of complete or substantial 
HC-3 knockdown was achieved using this 
method.
The optimized procedure described in this 
report is novel in three important ways. First, 
cell viability and expression knockdown was 
dependent on shaking the cultures at 190 rpm 
throughout the procedure. Although the 
manufacturer recommends immediate 
swirling after Endo-Porter administration, 
it is likely that continual shaking throughout 
the incubation period contributed to the high 
efficiency of Endo-Porter–mediated PMO 
delivery by increasing cell exposure to these 
reagents. Thus, continual shaking of adherent 
as well as nonadherent cell cultures from any 
source (mammalian and nonmammalian) 
may also result in improved PMO-mediated 
expression knockdown through increased 
delivery efficiency. Second, while frog eryth-
rocytes do possess endocytic capacity (17,18), 
initial attempts at administering Endo-Porter 
and HC-3 PMO to erythrocytes cultured at 
~23°C (which is within the range of normal 
physiological temperature for treefrogs) 
failed to achieve successful HC-3 expression 
knockdown. Therefore, we implemented 
a pre-incubation step at 37°C prior to the 
administration of Endo-Porter and PMO 
in an attempt to recapitulate the kinetic and 
thermal conditions for which the delivery 
vehicle was created. In addition, this 37°C 
pre-incubation step likely functions to 
increase the membrane fluidity of the cells, 
thereby improving the efficiency of peptide-
mediated endocytosis (19). Third, prelim-
inary experimental trials indicated the need 
for a second round of Endo-Porter and PMO 
administration for efficient knockdown. This 
is consistent with prior studies (20) and with 
manufacturer’s recommendations (personal 
communication). In the procedure used here, 
a second 37°C incubation step was added 
prior to a second PMO administration, 
thereby coupling the effects of second-round 
Figure 2. Immunocytochemistry of HC-3 expression in cultured erythrocytes. Immuncytochemistry 
was performed on cultured erythrocytes using a primary peptide-derived polyclonal antibody directed 
against the C terminus of H. chrysoscelis HC-3. (A) No treatment (control). (B) 10 µM Endo-Porter alone 
(EP). (C) 3 µM HC-3 PMO alone (HC-3 M). (D) 10 µM Endo-Porter and 3 µM HC-3 PMO (EP + HC-3 M). 
(E) 10 µM Endo-Porter and 3 µM standard control PMO (EP + control M). (F) Pre-absorption control. 
HC-3 expression is shown as a green signal due to the use of a fluorescein labeled secondary anti-
body. Nuclei appear red after RNase treatment and propidium iodide staining. Approximately 30% of 
erythrocytes treated with EP + HC-3 M (panel D) showed complete HC-3 knockdown as assessed by 
the absence of fluorescence while >65% of erythrocytes had substantial reduction in HC-3 expression 
compared with treatment controls (Panels A–C and E) (n = 3 independent trials for each condition). No 
HC-3 signal (green) was seen in the pre-absorption controls (Panel F), where the HC-3 primary anti-
body was pre-incubated with 200-fold excess of the antigenic peptide, indicating that the HC-3 immu-
noreactivity seen in panels A–E is specific for the HC-3 antibody. Images were taken using an Olympus 
FluoView 1000 laser scanning confocal microscope (Center Valley, PA, USA) with a 60× objective. The 
scale bar indicates 50 µm.
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PMO exposure with improved membrane fluidity. The combination 
of all three optimization steps was required to achieve targeted gene 
knockdown in our system. By using this improved and optimized 
approach, we achieved >95% targeted expression knockdown.
In conclusion, a novel procedure for efficient Endo-Porter–
mediated HC-3 PMO delivery and expression knockdown in cultured 
amphibian erythrocytes has been described. This model will be used 
in future experiments to determine HC-3 function in freeze tolerance. 
However, the utility of this optimized delivery method is not restricted 
to amphibian erythrocytes. This novel procedure is likely to be of 
special interest and utility to investigators using nonmammalian 
systems (e.g., Xenopus, zebrafish, sea urchin, fish, newt, axolotl) who 
may not have previously attempted to use Endo-Porter due to concerns 
about its efficacy at nonoptimal temperatures. Moreover, the combi-
nation of optimized steps can be broadly applied to mammalian as well 
as nonmammalian systems in order to improve overall knockdown 
efficiency. Finally, this report demonstrates that Endo-Porter–mediated 
PMO expression knockdown can be optimized for use in models for 
which genetic knockout tools do not currently exist.
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